سعر Vigam-S 5% w/v 2026

Vigam-S 5% w/v human normal immunoglobulin for IV infusion, 50 ml vial.

• Very common: pyrexia. Common: headache, hypertension, hypotension, pharyngitis, nausea, vomiting, rash, urticaria, arthralgia, infusion-site pain, lethargy, fatigue.International label, equivalent formulation · MinClinic (reproduction of UK SmPC)

• Hypersensitivity to human immunoglobulins or excipients; selective IgA deficiency with anti-IgA antibodies.International label, equivalent formulation · MinClinic (reproduction of UK SmPC)

• Risks include infusion reactions, hypersensitivity/anaphylaxis, thromboembolism, acute renal failure (product contains sucrose), aseptic meningitis, haemolytic anaemia, neutropenia, TRALI and transmission of infective agents.International label, equivalent formulation · MinClinic (reproduction of UK SmPC)

• Live attenuated virus vaccinesMay impair vaccine efficacy for 6 weeks to 3 months (measles up to 1 year); wait 3 months before vaccination.MinClinic (reproduction of UK SmPC)
• Loop diureticsAvoid concomitant use.MinClinic (reproduction of UK SmPC)

• Safety in pregnancy not established in controlled trials; give with caution. Clinical experience suggests no harmful effects on pregnancy, foetus or neonate; IVIg crosses the placenta, increasingly in the third trimester.International label, equivalent formulation · MinClinic (reproduction of UK SmPC)
• Immunoglobulins are excreted into human milk; no negative effects on breastfed infants are anticipated.International label, equivalent formulation · MinClinic (reproduction of UK SmPC)

• Human normal immunoglobulin: Supplies a broad spectrum of IgG antibodies present in the normal population, restoring low IgG levels; mechanism in non-replacement indications not fully elucidated.